
Opinion|Videos|September 30, 2024
Evolving First-Line Treatment Strategies in Metastatic RCC: Key Factors Shaping Decision-Making
Author(s)Rana R. McKay, MD
Panelists discuss how the first-line treatment landscape for metastatic renal cell carcinoma has evolved in recent years, considering various factors that influence decision-making for newly diagnosed patients.
Advertisement
Episodes in this series

Now Playing
- How has the first-line treatment landscape for metastatic renal cell carcinoma (mRCC) evolved in recent years?
- What factors influence your decision for newly diagnosed mRCC patients?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















